BAYRY
Not a breakup. Not today.
Bayer just told investors to pump the brakes on the breakup fantasy. A company rep said the German giant is not currently discussing a Monsanto spin-off, even though activist investors have been pushing for exactly that kind of shake-up.
That matters because Monsanto isn’t just a line item on a slide deck — it’s the baggage that came with Bayer’s $63 billion acquisition in 2018. And baggage, as it turns out, can be wildly expensive.
The Roundup cloud won’t leave the room
Roundup litigation is still the main villain in this story. Bayer inherited thousands of lawsuits alleging the weedkiller causes cancer, and the company has already burned through billions settling claims.
A Bayer executive reportedly warned that if the legal mess doesn’t get resolved, it could even affect U.S. production of glyphosate-based products. That’s a fancy way of saying the lawsuit overhang isn’t just a courtroom problem — it’s creeping into operations too.
Why investors still care
For shareholders, this is one of those annoying situations where “no big change” is still very much news. Keeping the current structure means Bayer is betting on:
- operational fixes
- litigation-related solutions
- time, patience, and maybe a little luck
Meanwhile, the stock is still sitting far below where it was before the Monsanto deal, which is a brutal reminder that big mergers can come with even bigger headaches.
Big picture: Bayer isn’t ripping up the Monsanto chapter yet. But until the Roundup legal saga gets real closure, investors are stuck watching the same old storm clouds hover over the stock.